AAAAAA

   
Results: 1-10 |
Results: 10
Cell growth inhibition, G(2)M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines
Authors: Zaffaroni, N De Marco, C Villa, R Riboldi, S Daidone, MG Double, JA
Citation: N. Zaffaroni et al., Cell growth inhibition, G(2)M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines, EUR J CANC, 37(15), 2001, pp. 1953-1962
A novel strategy for NQO1 (NAD(P)H : quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9
Authors: Choudry, GA Stewart, PAH Double, JA Krul, MRL Naylor, B Flannigan, GM Shah, TK Brown, JE Phillips, RM
Citation: Ga. Choudry et al., A novel strategy for NQO1 (NAD(P)H : quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9, BR J CANC, 85(8), 2001, pp. 1137-1146
Genotyping of NAD(P)H : quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo
Authors: Phillips, RM Burger, AM Fiebig, HH Double, JA
Citation: Rm. Phillips et al., Genotyping of NAD(P)H : quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo, BIOCH PHARM, 62(10), 2001, pp. 1371-1377
Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 4: Variation of the basic structure
Authors: Aitken, RA Bibby, MC Cooper, PA Double, JA Laws, AL Ritchie, RB Wilson, DWJ
Citation: Ra. Aitken et al., Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 4: Variation of the basic structure, ARCH PHARM, 333(6), 2000, pp. 181-188
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
Authors: Patterson, LH McKeown, SR Ruparella, K Double, JA Bibby, MC Cole, S Stratford, IJ
Citation: Lh. Patterson et al., Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent, BR J CANC, 82(12), 2000, pp. 1984-1990
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor modelswith differing responses to PK1
Authors: Loadman, PM Bibby, MC Double, JA Al-Shakhaa, WM Duncan, R
Citation: Pm. Loadman et al., Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor modelswith differing responses to PK1, CLIN CANC R, 5(11), 1999, pp. 3682-3688
In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans
Authors: Calabrese, CR Loadman, PM Lim, LSE Bibby, MC Double, JA Brown, JE Lamb, JH
Citation: Cr. Calabrese et al., In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans, DRUG META D, 27(2), 1999, pp. 240-245
Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311
Authors: Burger, AM Jenkins, TC Double, JA Bibby, MC
Citation: Am. Burger et al., Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311, BR J CANC, 81(2), 1999, pp. 367-375
Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 3: 2-heteroaryl derivatives
Authors: Aitken, RA Bibby, MC Bielefeldt, F Double, JA Laws, AL Mathieu, AL Ritchie, RB Wilson, DWJ
Citation: Ra. Aitken et al., Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 3: 2-heteroaryl derivatives, ARCH PHARM, 331(12), 1998, pp. 405-411
Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs
Authors: Phillips, RM Pearce, J Loadman, PM Bibby, MC Cooper, PA Swaine, DJ Double, JA
Citation: Rm. Phillips et al., Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs, CANCER RES, 58(23), 1998, pp. 5263-5266
Risultati: 1-10 |